Rua Bioscience Limited Analysis

Overview

Rua is a New Zealand pharmaceutical company that is aiming to be a leading producer of cannabinoid derived medicines. The Company was established in 2017 in part to support local economic development in the Tairāwhiti (East Coast) region, and is a pioneer in the New Zealand medicinal cannabis sector. It was the first company in New Zealand to obtain a licence to cultivate cannabis for research purposes and the Company’s co-founder was actively involved in both the establishment of the key industry association and the development of the regulatory framework that is now in place to govern the sector. Rua will operate in the research, cultivation, extraction and manufacturing parts of the medicinal cannabis supply chain.

Performance

The following information has been extracted from Rua Bioscience Limited's half year results, released on 27 February 2026

The Group reported sales revenue from customers of $1,333,773 for the 6 month period compared to $693,829 for the prior corresponding period, an improvement of 92%. Whilst revenue increased significantly, net loss before tax improved only slightly to $1,793,429 for the period compared to a loss of $1,802,255 in the prior corresponding period. The increase in revenue and gross margin was offset by increases to financing costs of inventory, non-cash share allocation costs to staff, and stock adjustments.

The net cash outflow from operating activities was $1,520,360 down 22% from $1,942,997 in the prior corresponding period. This improvement is attributed to continued focus on improvement of our capital light operating model, particularly outsourcing commercial manufacturing.

During the period the company raised further capital to fund the growth in sales. The company undertook a pro-rata rights offer to all shareholders and a placement of new shares which raised $2,315,679. After associated costs, the company received cash of $2,022,750 during the period.